Roberta D'ambrosio

List of Publications by Year
in descending order

89	3,591	201674 27	138484 58
papers	citations	h-index	g-index

89	89	89	5082
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. Hepatology, 2016, 63, 827-838.	7.3	467
2	A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology, 2012, 56, 532-543.	7.3	354
3	High rates of 30-day mortality in patients with cirrhosis and COVID-19. Journal of Hepatology, 2020, 73, 1063-1071.	3.7	279
4	Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. Journal of Hepatology, 2017, 66, 485-493.	3.7	225
5	Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. Journal of Hepatology, 2021, 74, 775-782.	3.7	193
6	Randomized Study of Peginterferon-Î±2a Plus Ribavirin vs Peginterferon-Î±2b Plus Ribavirin in Chronic Hepatitis C. Gastroenterology, 2010, 138, 108-115.	1.3	190
7	The diagnostic accuracy of FibroscanÂ® for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response. Journal of Hepatology, 2013, 59, 251-256.	3.7	131
8	Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C. Journal of Hepatology, 2019, 70, 379-387.	3.7	109
9	Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Scientific Reports, 2019, 9, 3682.	3.3	85
10	Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C. Hepatology, 2012, 56, 1681-1687.	7.3	83
11	Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. Hepatology, 2012, 55, 336-342.	7.3	81
12	Direct-acting antivirals: the endgame for hepatitis C?. Current Opinion in Virology, 2017, 24, 31-37.	5.4	81
13	Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection. Clinical Gastroenterology and Hepatology, 2019, 17, 1183-1191.e7.	4.4	79
14	Patatin-like phospholipase domain-containing 3 I148M affects liver steatosis in patients with chronic hepatitis B. Hepatology, 2013, 58, 1245-1252.	7.3	69
15	A novel autoantigen to differentiate limited cutaneous systemic sclerosis from diffuse cutaneous systemic sclerosis: The interferon-inducible gene IFI16. Arthritis and Rheumatism, 2006, 54, 3939-3944.	6.7	64
16	Contribution of Î²-cell dysfunction and insulin resistance to cirrhosis-associated diabetes: Role of severity of liver disease. Journal of Hepatology, 2015, 63, 1484-1490.	3.7	61
17	Hepatocellular Carcinoma in Patients with a Sustained Response to Anti-Hepatitis C Therapy. International Journal of Molecular Sciences, 2015, 16, 19698-19712.	4.1	57
18	Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients. Hepatology, 2015, 62, 111-117.	7.3	52

#	Article	IF	Citations
19	The Course of Esophageal Varices in Patients with Hepatitis C Cirrhosis Responding to Interferon/ Ribavirin Therapy. Antiviral Therapy, 2011, 16, 677-684.	1.0	48
20	Hepatic Fatâ€"Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs. Hepatology, 2020, 72, 1912-1923.	7.3	48
21	Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR. Journal of Hepatology, 2022, 76, 302-310.	3.7	48
22	Treatment of hepatitis C virus infection with directâ€acting antiviral drugs is safe and effective in patients with hemoglobinopathies. American Journal of Hematology, 2017, 92, 1349-1355.	4.1	42
23	Liver fibrosis and CD206+ macrophage accumulation are suppressed by anti-GM-CSF therapy. JHEP Reports, 2020, 2, 100062.	4.9	42
24	Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis. Journal of Hepatology, 2020, 73, 593-602.	3.7	38
25	Definition of Healthy Ranges for Alanine Aminotransferase Levels: A 2021 Update. Hepatology Communications, 2021, 5, 1824-1832.	4.3	37
26	Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy. Journal of Viral Hepatitis, 2013, 20, 858-866.	2.0	32
27	The pattern of pegylated interferon-Î±2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype. Antiviral Therapy, 2009, 14, 577-584.	1.0	30
28	Should surveillance for liver cancer be modified in hepatitis C patients after treatmentâ€related cirrhosis regression?. Liver International, 2016, 36, 783-790.	3.9	29
29	Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2008-e2020.	3.6	27
30	Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon. PLoS ONE, 2016, 11, e0155967.	2.5	23
31	Sofosbuvirâ€based regimens for the treatment of hepatitis C virus in patients who underwent lung transplant: case series and review of the literature. Liver International, 2016, 36, 1585-1589.	3.9	22
32	Persistence of hepatocellular carcinoma risk in hepatitis C patients with a response to <scp>IFN</scp> and cirrhosis regression. Liver International, 2018, 38, 1459-1467.	3.9	22
33	Hyporesponsiveness to PegIFNÎ±2B plus ribavirin in patients with hepatitis C-related advanced fibrosis. Journal of Hepatology, 2012, 56, 341-347.	3.7	21
34	The Association of Il28b Genotype with the Histological Features of Chronic Hepatitis C Is HCV Genotype Dependent. International Journal of Molecular Sciences, 2014, 15, 7213-7224.	4.1	19
35	Telaprevir in a Patient with Chronic Hepatitis C and Cryoglobulinemic Glomerulonephritis. Antiviral Therapy, 2014, 19, 527-531.	1.0	18
36	Evaluation of coagulation during treatment with directly acting antivirals in patients with hepatitis C virus related cirrhosis. Liver International, 2017, 37, 1295-1303.	3.9	18

#	Article	IF	Citations
37	The pattern of pegylated interferon-alpha2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype. Antiviral Therapy, 2009, 14, 577-84.	1.0	16
38	Comparison of three therapeutic regimens for genotypeâ€3 hepatitis C virus infection in a large realâ€life multicentre cohort. Liver International, 2020, 40, 769-777.	3.9	15
39	The relationship between liver histology and thyroid function tests in patients with non-alcoholic fatty liver disease (NAFLD). PLoS ONE, 2021, 16, e0249614.	2.5	15
40	Impaired Response to Interferon-Î±2B plus Ribavirin in Cirrhotic Patients with Genotype 3A Hepatitis C Virus Infection. Antiviral Therapy, 2006, 11, 797-802.	1.0	15
41	Safety of direct antiviral agents in real life. Digestive and Liver Disease, 2013, 45, S363-S366.	0.9	14
42	Hepatitis C Virus Deletion Mutants Are Found in Individuals Chronically Infected with Genotype 1 Hepatitis C Virus in Association with Age, High Viral Load and Liver Inflammatory Activity. PLoS ONE, 2015, 10, e0138546.	2.5	14
43	Limited Utility of ITPA Deficiency to Predict Early Anemia in HCV Patients with Advanced Fibrosis Receiving Telaprevir. PLoS ONE, 2014, 9, e95881.	2.5	13
44	High rate of sustained virological response with directâ€acting antivirals in haemophiliacs with HCV infection: A multicenter study. Liver International, 2020, 40, 1062-1068.	3.9	13
45	Implementation of HCV screening in the 1969â€“1989 birthâ€cohort undergoing COVIDâ€19 vaccination. Liver International, 2022, 42, 1012-1016.	3.9	13
46	Acute Tubular Necrosis Following Interferon-Based Therapy for Hepatitis C: Case Study with Literature Review. Kidney and Blood Pressure Research, 2013, 38, 52-60.	2.0	12
47	Statins May Increase the Risk of Liver Dysfunction in Patients Treated With Steroids for Active Graves' Orbitopathy. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1731-1737.	3.6	12
48	Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study. Digestive and Liver Disease, 2020, 52, 190-198.	0.9	12
49	Decompensation in Direct-Acting Antiviral Cured Hepatitis C Virus Compensated Patients With Clinically Significant Portal Hypertension: Too Rare to Warrant Universal Î²-Blocker Therapy. American Journal of Gastroenterology, 2021, 116, 1342-1344.	0.4	12
50	Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: Is there still an indication?. Digestive and Liver Disease, 2016, 48, 650-655.	0.9	11
51	Prothrombin induced by vitamin K absence or antagonistâ€II and alpha foetoprotein to predict development of hepatocellular carcinoma in Caucasian patients with hepatitis Câ€related cirrhosis treated with directâ€acting antiviral agents. Alimentary Pharmacology and Therapeutics, 2022, 55, 350-359.	3.7	11
52	Ribavirin Impairs Salivary Gland Function in Hepatitis C Patients During Combination Treatment With Pegylated Interferon Alfa-2a. Hepatitis Monthly, 2011, 11, 918-924.	0.2	10
53	TLL1 variants do not predict hepatocellular carcinoma development in HCV cirrhotic patients treated with directâ€acting antivirals. Journal of Viral Hepatitis, 2019, 26, 1233-1236.	2.0	10
54	Reply to: Correspondence on â€œHigh rates of 30-day mortality in patients with cirrhosis and COVID-19â€. Journal of Hepatology, 2020, 73, 1570-1571.	3.7	10

#	Article	IF	Citations
55	Predicting Hepatocellular Carcinoma Risk in Patients with Chronic HCV Infection and a Sustained Virological Response to Direct-Acting Antivirals. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 713-739.	3.7	10
56	Treatment of Patients With HCV Related Cirrhosis: Many Rewards With Very Few Risks. Hepatitis Monthly, 2012, 12, 361-368.	0.2	9
57	Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C. Expert Opinion on Drug Safety, 2015, 14, 473-484.	2.4	9
58	Impact of hepatitis C virus and direct acting antivirals on kidney recipients: a retrospective study. Transplant International, 2019, 32, 493-501.	1.6	9
59	Interaction between PNPLA3 I148M Variant and Age at Infection in Determining Fibrosis Progression in Chronic Hepatitis C. PLoS ONE, 2014, 9, e106022.	2.5	9
60	Procoagulant imbalance influences cardiovascular and liver damage in chronic hepatitis C independently of steatosis. Liver International, 2019, 39, 2309-2316.	3.9	8
61	Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort. Hepatology International, 2020, 14, 362-372.	4.2	8
62	Clinical exome sequencing for diagnosing severe cryptogenic liver disease in adults: A case series. Liver International, 2022, 42, 864-870.	3.9	8
63	Lack of Rapid Virological Response Predicts Interferon-Î±2b/Ribavirin Therapy failure in HCV Genotype 2 Patients: A Single-Centre Study. Antiviral Therapy, 2007, 12, 1033-1040.	1.0	8
64	A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-Î²1 dependent mechanisms. Scientific Reports, 2019, 9, 1439.	3.3	7
65	Liver damage and sickle cell disease: genotype relationship. Annals of Hematology, 2020, 99, 2065-2072.	1.8	7
66	Suboptimal accuracy of GES score to stratify postâ€SVR HCC risk in a single center cohort of European cirrhotics infected with any HCV genotype. Liver International, 2021, 41, 1152-1153.	3.9	7
67	Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Realâ€Life Cohort Study. Hepatology Communications, 2022, 6, 867-877.	4.3	6
68	Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection. Antiviral Therapy, 2006, 11, 797-802.	1.0	6
69	De Novo Membrano-Proliferative Nephritis Following Interferon Therapy for Chronic Hepatitis C (Case Study and Literature Review). Digestive Diseases and Sciences, 2014, 59, 691-695.	2.3	5
70	Assessing spleen stiffness by point shearâ€wave elastography: Is it feasible and reproducible in patients with chronic liver disease? Is it useful to predict portal hypertension?. GastroHep, 2019, 1, 205-213.	0.6	3
71	High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCVâ€infected patients treated in a realâ€life setting. Journal of Viral Hepatitis, 2021, 28, 558-568.	2.0	3
72	The clinical impact of a 24-week treatment course of peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. Journal of Hepatology, 2006, 44, 825.	3.7	2

#	Article	IF	Citations
73	Acute Allograft Rejection following Interferon Therapy for Hepatitis C in Recipients who have Returned to Dialysis after Kidney Transplant Failure: Case Study. International Journal of Artificial Organs, 2014, 37, 803-808.	1.4	2
74	The CCR5 and CXCR3 Pathways in Hepatitis C Virus Liver Transplanted Recipients Treated by a Direct Antiviral Agent Regimen: Informative Kinetics Profiles. Viral Immunology, 2021, 34, 542-551.	1.3	2
75	Lack of rapid virological response predicts interferon-alpha2b/ribavirin therapy failure in HCV genotype 2 patients: a single-centre study. Antiviral Therapy, 2007, 12, 1033-40.	1.0	2
76	Is it time to refine HCC surveillance strategies in HCV cured patients?. Hepatology, 2022, 76, 9-11.	7.3	2
77	Treatment of experienced and naïve patients with hepatitis C: focus on telaprevir. Biologics: Targets and Therapy, 2012, 6, 363.	3.2	1
78	Chemokine Receptor 5 Has No Major Role in the Severity of Hepatitis C Virus-Related Liver Damage. Viral Immunology, 2018, 31, 358-361.	1.3	1
79	THU-166-Treatment of 320 genotype 3 cirrhotic patients with 12 weeks of sofosbuvir/velpatasvir with or without ribavirin: Real life experience from Italy. Journal of Hepatology, 2019, 70, e234-e235.	3.7	1
80	Effectiveness and safety of sofosbuvir-based direct-acting antiviral combinations in HCV-2 and HCV-3 kidney transplant recipients. Kidney International, 2019, 95, 993-995.	5.2	1
81	Combination of CLIF-OF and CCI predicts survival in patients with cirrhosis and COVID-19. Gut, 2021, 70, 1798-1799.	12.1	1
82	A new algorithm shows superior ability to discriminate liver fibrosis stages in chronic hepatitis C. Journal of Viral Hepatitis, 2021, 28, 1443-1451.	2.0	1
83	Hepatocellular Carcinoma Risk, Outcomes, and Screening After Hepatitis C Eradication. Hepatology Communications, 2021, 5, 1465-1468.	4.3	1
84	Proteomics to Predict Hepatitis C Therapy Outcome: Where Do We Stand?. Gastroenterology, 2012, 142, 1034-1037.	1.3	0
85	P143: Concordance between SVR4 and SVR24 in DAA Based Regimens: a real life experience including postâ€liver transplant patients. Journal of Viral Hepatitis, 2015, 22, 91-92.	2.0	0
86	Treating hepatitis C in patients with hemoglobinopathies. Expert Opinion on Orphan Drugs, 2015, 3, 1267-1278.	0.8	0
87	Do ITPA gene variants provide insight to detecting patients infected with HCV 2/1 recombinant strains?. Hepatology, 2016, 64, 322-323.	7.3	0
88	12 weeks ombitasvir/paritaprevirâ€"ritonavirâ€¯+â€¯ribavirin achieve high SVR rates in HCV-4 patients with advanced fibrosis. Digestive and Liver Disease, 2018, 50, 703-706.	0.9	0
89	Editorial: the role for PIVKAâ€II measurement after HCV elimination by directâ€acting antivirals in terms of prediction of hepatocellular carcinomaâ€"authors' reply. Alimentary Pharmacology and Therapeutics, 2022, 55, 124-125.	3.7	0